- Home
- XXII vs QNRX Comparison
XXII vs QNRX Comparison
Compare XXII & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- QNRX
- Stock Information
- Founded
- XXII 1998
- QNRX 2018
- Country
- XXII United States
- QNRX United States
- Employees
- XXII N/A
- QNRX N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- QNRX Medical/Dental Instruments
- Sector
- XXII Health Care
- QNRX Health Care
- Exchange
- XXII Nasdaq
- QNRX Nasdaq
- Market Cap
- XXII 2.8M
- QNRX 2.7M
- IPO Year
- XXII N/A
- QNRX N/A
- Fundamental
- Price
- XXII $3.15
- QNRX $0.32
- Analyst Decision
- XXII
- QNRX Strong Buy
- Analyst Count
- XXII 0
- QNRX 1
- Target Price
- XXII N/A
- QNRX $4.00
- AVG Volume (30 Days)
- XXII 166.3K
- QNRX 4.1M
- Earning Date
- XXII 03-27-2025
- QNRX 03-12-2025
- Dividend Yield
- XXII N/A
- QNRX N/A
- EPS Growth
- XXII N/A
- QNRX N/A
- EPS
- XXII N/A
- QNRX N/A
- Revenue
- XXII $17,304,000.00
- QNRX N/A
- Revenue This Year
- XXII $56.94
- QNRX N/A
- Revenue Next Year
- XXII $2.98
- QNRX N/A
- P/E Ratio
- XXII N/A
- QNRX N/A
- Revenue Growth
- XXII N/A
- QNRX N/A
- 52 Week Low
- XXII $3.01
- QNRX $0.28
- 52 Week High
- XXII $581.85
- QNRX $6.18
- Technical
- Relative Strength Index (RSI)
- XXII 35.94
- QNRX 38.39
- Support Level
- XXII $3.01
- QNRX $0.30
- Resistance Level
- XXII $3.47
- QNRX $0.35
- Average True Range (ATR)
- XXII 0.33
- QNRX 0.04
- MACD
- XXII 0.11
- QNRX 0.01
- Stochastic Oscillator
- XXII 11.29
- QNRX 17.24
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.